Paul Sugarbaker and his colleagues have persevered in the study and treat­ ment of peritoneal carcinomatosis. The peritoneal cavity has many unique and incompletely appreciated properties. These properties, coupled with the biologic behavior of many cancers, results in the seeding and growth of these cancers on the peritoneum. Many of these cancers remain localized to the peritoneum only, never metastasizing to other sites. One possible reason for this may be the obstruction of the afferent lymphatics on the undersurface of the diaphragm. The mucopolysaccharides produced by many of these neoplasma are probably viscous enough to obstruct these lymphatics, leading to the syndrome of pseudomyxoma peritonei. Many of the neoplasms taking residence on the peritoneum have extremely long cell-cycle times and are resistant to radiotherapy and many chemotherapeutic agents. How­ ever, much can be done for these patients - resection of primary cancers, omentectomies to reduce ascites formation, management of recurrent ascites, management of intestinal obstruction, nutritional care, and, hopefully, intraperitoneal chemotherapy. We have reviewed many of these problems in the past [1-7]. Dr. Sugarbaker and his colleagues have organized the current state of knowledge and technology for continuing use. The book provides a basis for thoughtful, prospective research planning. John S. Spratt, M. D. , F. A. C. S. Professor of Surgery The James Graham Brown Cancer Center University of Louisville Louisville, Kentucky References 1. Long RTL, Spratt JS, Dowling E.

Inhalt

Foreword; J. Spratt. Preface; P.H. Sugarbaker. Section I: General principles. 1. Metastatic inefficiency: intravascular and intraperitoneal implantation of cancer cells; L. Weiss. 2. Intraperitoneal immunotherapy of cancer: a review of options for treatment; H.H. van Ravenswaay, A.M.M. Eggermont. 3. Pharmacokinetics of the peritoneal-plasma barrier after systematic mitomycin C administration; P.H. Sugarbaker, et al. 4. The peritoneal plasma barrier; P. Jacquet. 5. Patterns of spread of recurrent intraabdominal sarcoma; T.A. Sugarbaker, et al. 6. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology; P.H. Sugarbaker. 7. In-vitro pharmacologic rationale for intraperitoneal regional chemotherapy; K. Link, et al. 8. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes; R. Freeman, C.D. Platsoucas. 9. The role of omentum associated lymphoid tissue in the progression of peritoneal carcinomatosis; M. Shimotsuma, et al. 10. Cancer cell seeding during abdominal surgery: experimental studies; F. Zoetmulder. 11. The Krukenberg syndrome as a natural manifestation of tumor cell entrapment; A.M. Averbach, P.H. Sugarbaker. Section II: Techniques. 12. Peritoneal carcinomatosis and radioimmunoguided surgery; S. Schneebaum, et al. 13. Diffuse and gross peritoneal carcinomatosis treated by intraperitoneal hyperthermic chemoperfusion; F. Kober, et al. 14. Intraperitoneal heated chemotherapy: a promise with problems; B. Loggie. 15. Peritonectomy procedures; P.H. Sugarbaker. 16. Progressive release of the left colon for a tension free colorectal or coloanal anastomosis; P.H. Sugarbaker. 17. Radiology of peritoneal carcinomatosis; A. Archer, et al. 18. Methodologic considerations in treatment using intraperitoneal chemotherapy; A.M. Averbach, et al. 19. Safety considerations in the use of intraoperative intraperitoneal chemotherapy; S. White, et al. 20. Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy; P.H. Sugarbaker. 21. The effects of postoperative intraperitoneal chemotherapy on peritoneal wound healing and adhesion formation; P. Jacquet, P.H. Sugarbaker. 22. Current status of staging laparoscopy in colorectal and ovarian cancer; M.P. Boente, et al. 23. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis; P. Jacquet, P.H. Sugarbaker. 24. Laser-mode electrosurgery; P.H. Sugarbaker. 25. Peritoneal access devices for intraperitoneal chemotherapy; S.R. Ash.